Iovance Biotherapeutics (IOVA) Financials

$3.59 +0.03 (+0.84%)

As of 04:00 PM Eastern

Annual Income Statements for Iovance Biotherapeutics

This table shows Iovance Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-12	-28	-102	-92	-124	-198	-260	-342	-396	-444	-372
Consolidated Net Income / (Loss)	-12	-28	-53	-92	-124	-198	-260	-342	-396	-444	-372
Net Income / (Loss) Continuing Operations	-12	-28	-53	-92	-124	-198	-260	-342	-396	-444	-372
Total Pre-Tax Income	-12	-28	-53	-92	-124	-198	-260	-342	-396	-448	-375
Total Operating Income	-12	-28	-54	-93	-128	-207	-262	-343	-399	-461	-395
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-9.57	40
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.19	164
Operating Revenue	0.00	0.00	0.00	-	-	-	-	0.00	0.00	1.19	164
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11	124
Operating Cost of Revenue	-	-	-	-	-	-	-	0.00	0.00	11	124
Total Operating Expenses	12	28	54	93	128	207	262	343	399	451	435
Selling, General & Admin Expense	8.19	12	27	21	28	41	60	84	104	107	153
Research & Development Expense	3.85	15	27	72	100	166	202	259	295	344	282
Total Other Income / (Expense), net	0.01	0.20	0.75	0.81	4.68	9.32	2.36	0.45	2.99	13	20
Interest & Investment Income	0.01	0.20	0.75	0.81	4.68	9.32	2.36	0.45	2.99	13	20
Income Tax Expense	-	-	-	-	-	-	-	0.00	0.00	-3.48	-2.83
Basic Earnings per Share	($0.48)	($0.62)	($1.85)	($1.41)	($1.27)	($1.59)	($1.88)	($2.23)	($2.49)	($1.89)	($1.28)
Weighted Average Basic Shares Outstanding	24.99M	44.41M	55.27M	65.24M	97.28M	124.34M	138.30M	153.41M	159.26M	235.13M	289.88M
Diluted Earnings per Share	($0.48)	($0.62)	($1.85)	($1.41)	($1.27)	($1.59)	($1.88)	($2.23)	($2.49)	($1.89)	($1.28)
Weighted Average Diluted Shares Outstanding	24.99M	44.41M	55.27M	65.24M	97.28M	124.34M	138.30M	153.41M	159.26M	235.13M	289.88M
Weighted Average Basic & Diluted Shares Outstanding	24.99M	44.41M	55.27M	65.24M	97.28M	124.34M	138.30M	157.17M	224.24M	279.31M	327.88M

This table shows Iovance Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-100	-105	-107	-107	-114	-116	-113	-97	-84	-79
Consolidated Net Income / (Loss)	-100	-105	-107	-107	-114	-116	-113	-97	-84	-79
Net Income / (Loss) Continuing Operations	-100	-105	-107	-107	-114	-116	-113	-97	-84	-79
Total Pre-Tax Income	-100	-105	-107	-107	-115	-118	-114	-99	-85	-77
Total Operating Income	-100	-107	-111	-110	-118	-121	-118	-102	-89	-87
Total Gross Profit	0.00	-	0.00	-1.81	-3.87	-3.88	-6.55	-0.26	19	28
Total Revenue	0.00	-	0.00	0.24	0.47	0.48	0.72	31	59	74
Operating Revenue	0.00	-	0.00	0.24	0.47	0.48	0.72	31	59	74
Total Cost of Revenue	0.00	-	0.00	2.05	4.34	4.37	7.26	31	40	46
Operating Cost of Revenue	0.00	-	0.00	2.05	4.34	4.37	7.26	31	40	46
Total Operating Expenses	100	107	111	108	114	117	111	102	108	115
Selling, General & Admin Expense	28	26	28	22	27	30	31	40	40	43
Research & Development Expense	73	81	83	86	88	87	80	62	68	72
Total Other Income / (Expense), net	0.78	1.72	3.49	3.08	3.36	3.12	3.34	3.36	4.01	9.58
Interest & Investment Income	0.78	1.72	3.49	3.08	3.36	3.12	3.34	3.36	4.01	9.58
Income Tax Expense	0.00	-	0.00	-0.48	-1.24	-1.76	-1.41	-1.46	-1.52	1.56
Basic Earnings per Share	($0.63)	($0.65)	($0.50)	($0.47)	($0.46)	($0.46)	($0.42)	($0.34)	($0.28)	($0.24)
Weighted Average Basic Shares Outstanding	157.82M	159.26M	213.69M	224.48M	245.82M	235.13M	266.22M	284.82M	303.27M	289.88M
Diluted Earnings per Share	($0.63)	($0.65)	($0.50)	($0.47)	($0.46)	($0.46)	($0.42)	($0.34)	($0.28)	($0.24)
Weighted Average Diluted Shares Outstanding	157.82M	159.26M	213.69M	224.48M	245.82M	235.13M	266.22M	284.82M	303.27M	289.88M
Weighted Average Basic & Diluted Shares Outstanding	157.84M	224.24M	224.45M	247.78M	255.92M	279.31M	279.83M	303.51M	304.78M	327.88M

This table details how cash moves in and out of Iovance Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	25	-11	73	39	-63	-63	53	11	154	-57	-59
Net Cash From Operating Activities	-8.63	-18	-33	-79	-101	-159	-205	-228	-293	-362	-353
Net Cash From Continuing Operating Activities	-8.63	-18	-33	-79	-101	-159	-205	-227	-293	-362	-353
Net Income / (Loss) Continuing Operations	-12	-28	-53	-92	-124	-198	-260	-342	-396	-444	-372
Consolidated Net Income / (Loss)	-12	-28	-53	-92	-124	-198	-260	-342	-396	-444	-372
Depreciation Expense	0.09	1.00	0.98	0.95	0.96	1.17	1.14	3.11	9.31	12	12
Amortization Expense	0.00	0.00	-0.07	0.02	-1.33	3.53	9.44	17	12	18	21
Non-Cash Adjustments To Reconcile Net Income	3.81	8.52	19	12	20	18	29	70	84	52	99
Changes in Operating Assets and Liabilities, net	-0.50	-0.24	0.42	0.42	2.67	16	14	25	-2.89	0.79	-113
Net Cash From Investing Activities	-1.59	-71	8.89	59	-386	90	-318	0.13	256	-155	-96
Net Cash From Continuing Investing Activities	-1.59	-71	8.89	59	-386	90	-318	0.13	256	-155	-96
Purchase of Property, Plant & Equipment	-1.59	-1.14	-1.52	-1.03	-1.20	-6.92	-47	-38	-20	-22	-11
Acquisitions	-	-	-	-	-	-	-	0.00	0.00	-213	-53
Purchase of Investments	0.00	-141	-110	-	-426	-418	-948	-725	-246	-206	-461
Sale and/or Maturity of Investments	0.00	71	121	60	41	515	677	763	523	286	428
Net Cash From Financing Activities	35	78	97	59	424	6.13	576	239	190	463	391
Net Cash From Continuing Financing Activities	35	78	97	59	424	6.13	576	239	190	463	391
Issuance of Common Equity	32	68	96	-	399	0.00	567	205	191	466	400
Other Financing Activities, net	3.22	9.96	1.22	59	26	6.13	9.38	34	-1.01	-2.73	-9.59
Effect of Exchange Rate Changes	-	-	-	-	-	-	-	0.00	0.00	-2.74	-0.54

This table details how cash moves in and out of Iovance Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	10	113	312	-253	38	-153	-41	94	-65	-48
Net Cash From Operating Activities	-64	-78	-100	-94	-84	-84	-122	-98	-59	-73
Net Cash From Continuing Operating Activities	-64	-78	-100	-95	-83	-84	-122	-98	-59	-73
Net Income / (Loss) Continuing Operations	-100	-105	-107	-107	-114	-116	-113	-97	-84	-79
Consolidated Net Income / (Loss)	-100	-105	-107	-107	-114	-116	-113	-97	-84	-79
Depreciation Expense	2.45	2.81	2.76	2.93	2.92	2.95	2.98	2.99	3.03	2.98
Amortization Expense	2.88	2.24	1.96	5.03	5.93	5.04	4.59	5.38	5.46	5.94
Non-Cash Adjustments To Reconcile Net Income	20	19	13	18	9.48	12	14	33	31	21
Changes in Operating Assets and Liabilities, net	10	3.37	-10	-14	12	13	-31	-43	-15	-24
Net Cash From Investing Activities	74	0.46	153	-157	-79	-73	-112	40	-49	24
Net Cash From Continuing Investing Activities	74	0.46	153	-157	-79	-73	-112	40	-49	24
Purchase of Property, Plant & Equipment	-1.39	-3.02	-5.66	-9.52	-3.58	-3.53	-4.17	-0.44	-2.29	-4.17
Purchase of Investments	-64	-96	-5.32	-	-93	-108	-142	-74	-157	-88
Sale and/or Maturity of Investments	139	99	164	62	21	38	87	115	110	116
Net Cash From Financing Activities	0.23	191	258	1.03	203	0.96	194	153	42	2.31
Net Cash From Continuing Financing Activities	0.23	191	258	1.03	203	0.96	194	153	42	2.31
Issuance of Common Equity	-	191	260	1.27	203	1.14	198	153	48	1.39
Other Financing Activities, net	0.23	-	-1.93	-0.25	-0.38	-0.18	-4.34	-0.61	-5.56	0.92
Effect of Exchange Rate Changes	-	-	0.00	-3.77	-1.99	3.02	-0.49	-0.13	1.25	-1.18

This table presents Iovance Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	47	106	172	155	481	345	768	777	664	780	910
Total Current Assets	45	104	170	149	475	316	636	508	479	308	457
Cash & Equivalents	45	34	107	145	82	14	67	78	232	115	116
Short-Term Investments	0.00	70	60	0.00	386	293	562	426	240	165	208
Accounts Receivable	-	-	-	-	-	-	-	-	0.00	0.15	69
Inventories, net	-	-	-	-	-	-	-	-	0.00	10	52
Prepaid Expenses	0.07	0.28	3.04	3.92	6.85	9.41	6.66	3.55	7.27	17	12
Plant, Property, & Equipment, net	1.53	1.68	2.37	2.45	2.68	8.54	59	101	105	114	109
Total Noncurrent Assets	0.00	0.00	0.00	3.63	2.76	20	73	71	73	358	344
Intangible Assets	-	-	-	-	-	-	-	-	0.00	229	282
Other Noncurrent Operating Assets	-	-	0.00	3.63	2.76	20	73	71	73	129	62
Total Liabilities & Shareholders' Equity	47	106	172	155	481	345	768	777	664	780	910
Total Liabilities	1.66	1.63	4.97	9.89	15	46	112	156	164	196	200
Total Current Liabilities	1.66	1.63	4.97	9.60	14	39	55	89	91	110	122
Accounts Payable	1.33	0.96	0.86	1.23	2.74	16	14	27	27	33	28
Accrued Expenses	0.33	0.67	4.11	8.36	12	16	35	57	52	69	82
Other Current Liabilities	-	-	-	-	-	7.25	6.28	5.06	13	7.78	13
Total Noncurrent Liabilities	0.00	0.00	0.00	0.30	0.23	6.60	57	66	73	85	78
Long-Term Debt	-	-	-	-	-	-	0.00	1.00	1.00	1.00	1.00
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	-	0.00	17	32
Other Noncurrent Operating Liabilities	-	-	-	-	0.23	6.60	57	65	72	67	44
Commitments & Contingencies	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	45	104	167	145	466	299	656	622	500	585	710
Total Preferred & Common Equity	45	104	167	145	466	299	656	622	500	585	710
Preferred Stock	0.00	-	-	-	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	45	104	167	145	466	299	656	622	500	585	710
Common Stock	121	208	324	395	839	869	1,487	1,795	2,069	2,594	3,096
Retained Earnings	-77	-104	-157	-249	-373	-571	-830	-1,172	-1,568	-2,012	-2,385
Accumulated Other Comprehensive Income / (Loss)	0.00	0.05	0.03	0.00	-0.04	0.22	0.02	-0.60	-0.90	2.53	-1.05

This table presents Iovance Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	546	825	757	852	870	964	991
Total Current Assets	370	638	275	383	386	482	499
Cash & Equivalents	118	543	230	268	134	229	164
Short-Term Investments	242	83	21	94	222	184	233
Accounts Receivable	-	-	0.03	-	0.23	32	56
Inventories, net	-	-	9.72	9.20	18	28	39
Prepaid Expenses	9.71	11	14	12	11	10	6.74
Plant, Property, & Equipment, net	101	110	113	113	112	111	113
Total Noncurrent Assets	69	71	303	357	366	371	380
Intangible Assets	-	-	236	224	294	295	307
Other Noncurrent Operating Assets	69	71	68	133	72	76	73
Total Liabilities & Shareholders' Equity	546	825	757	852	870	964	991
Total Liabilities	152	158	179	178	190	196	218
Total Current Liabilities	79	87	89	91	83	94	118
Accounts Payable	24	32	31	19	26	20	32
Accrued Expenses	48	43	47	61	46	62	75
Other Current Liabilities	7.17	13	11	10	11	11	12
Total Noncurrent Liabilities	73	71	90	87	107	102	100
Long-Term Debt	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	20	18	33	32	32
Other Noncurrent Operating Liabilities	72	70	69	68	72	69	66
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	394	667	579	674	680	769	773
Total Preferred & Common Equity	394	667	579	674	680	769	773
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	394	667	579	674	680	769	773
Common Stock	1,859	2,343	2,360	2,579	2,805	2,990	3,063
Retained Earnings	-1,463	-1,676	-1,782	-1,896	-2,125	-2,222	-2,306
Accumulated Other Comprehensive Income / (Loss)	-2.04	-0.13	0.33	-9.10	0.12	0.53	16

This table displays calculated financial ratios and metrics derived from Iovance Biotherapeutics' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	13,698.99%
EBITDA Growth	52.05%	-124.72%	-96.33%	-74.28%	-39.96%	-57.17%	-24.33%	-28.39%	-16.91%	-14.25%	16.03%
EBIT Growth	51.71%	-131.38%	-92.53%	-73.15%	-38.09%	-61.29%	-26.62%	-30.83%	-16.39%	-15.46%	14.17%
NOPAT Growth	46.82%	-131.38%	-92.53%	-73.15%	-38.09%	-61.29%	-26.62%	-30.83%	-16.39%	-15.46%	14.17%
Net Income Growth	52.58%	-129.83%	-91.23%	-74.05%	-34.23%	-59.86%	-31.40%	-31.85%	-15.67%	-12.16%	16.18%
EPS Growth	86.17%	-29.17%	-198.39%	23.78%	9.93%	-25.20%	-18.24%	-18.62%	-11.66%	24.10%	32.28%
Operating Cash Flow Growth	-135.81%	-112.92%	-77.73%	-140.94%	-28.64%	-56.93%	-29.11%	-11.12%	-28.44%	-23.59%	2.44%
Free Cash Flow Firm Growth	42.39%	-90.63%	-89.41%	-71.67%	-35.05%	-59.18%	-57.18%	-6.81%	-20.39%	-115.58%	40.81%
Invested Capital Growth	96.91%	604.69%	38.70%	-75.89%	-2,257.41%	-248.07%	433.67%	-23.96%	8.68%	1,267.20%	26.78%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	68.18%	80.58%
EBITDA Q/Q Growth	35.89%	-14.33%	-16.50%	-12.47%	-8.25%	-12.59%	18.77%	-41.10%	-2.12%	-2.69%	8.96%
EBIT Q/Q Growth	35.51%	-14.89%	-16.11%	-12.27%	-7.43%	-17.07%	17.49%	-35.56%	-1.93%	-3.19%	8.07%
NOPAT Q/Q Growth	35.51%	-14.89%	-16.11%	-12.27%	-7.43%	-17.07%	17.49%	-35.56%	-1.93%	-3.19%	8.07%
Net Income Q/Q Growth	35.52%	-14.45%	-16.08%	-12.41%	-5.75%	-18.61%	-1.90%	-9.94%	-1.54%	-2.55%	9.22%
EPS Q/Q Growth	52.94%	-21.57%	-8.82%	-2.17%	7.30%	-18.66%	2.59%	-8.78%	-0.40%	9.13%	14.67%
Operating Cash Flow Q/Q Growth	-14.04%	-21.60%	-20.60%	-12.60%	-11.68%	-16.30%	-4.52%	3.73%	-8.86%	-1.77%	2.94%
Free Cash Flow Firm Q/Q Growth	25.62%	46.70%	-203.80%	-7.57%	-15.43%	-13.29%	3.62%	-4.24%	-9.16%	-1.31%	1.57%
Invested Capital Q/Q Growth	88.47%	-98.37%	396.69%	-94.76%	60.10%	-19.07%	1,273.00%	-53.90%	-20.51%	-2.52%	2.83%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-804.54%	24.43%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-36,252.06%	-220.60%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-38,734.99%	-240.92%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-38,734.99%	-240.92%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-37,345.42%	-226.84%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	99.22%	99.25%
Interest Burden Percent	99.95%	99.28%	98.61%	99.12%	96.35%	95.50%	99.10%	99.87%	99.25%	97.17%	94.87%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-196.51%	-79.81%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-164.34%	-48.07%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	114.61%	22.33%
Return on Equity (ROE)	-38.54%	-37.16%	-39.04%	-58.94%	-40.41%	-51.64%	-54.34%	-53.55%	-70.61%	-81.91%	-57.48%
Cash Return on Invested Capital (CROIC)	0.00%	-6,157.59%	-9,772.32%	-23,263.99%	0.00%	0.00%	-807.53%	-979.92%	-1,308.81%	-369.25%	-103.43%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-63.77%	-46.76%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-61.49%	-44.02%
Return on Common Equity (ROCE)	-38.54%	-37.16%	-39.04%	-58.94%	-40.41%	-51.64%	-54.34%	-53.55%	-70.61%	-81.91%	-57.48%
Return on Equity Simple (ROE_SIMPLE)	-26.84%	-26.59%	-31.69%	-63.28%	-26.51%	-66.08%	-39.54%	-55.05%	-79.24%	-75.95%	-52.39%
Net Operating Profit after Tax (NOPAT)	-8.43	-20	-38	-65	-90	-145	-183	-240	-279	-322	-277
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-27,114.49%	-168.64%
Net Nonoperating Expense Percent (NNEP)	-11.17%	-10.98%	-11.36%	-17.35%	-11.01%	-13.60%	-16.28%	-16.64%	-21.64%	-32.18%	-31.74%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-55.77%	-55.05%	-38.89%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	904.54%	75.57%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8,992.09%	93.26%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	28,938.35%	172.08%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	37,930.45%	265.35%
Earnings before Interest and Taxes (EBIT)	-12	-28	-54	-93	-128	-207	-262	-343	-399	-461	-395
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-12	-27	-53	-92	-129	-202	-251	-323	-377	-431	-362
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.85	3.55	2.59	3.99	2.34	11.68	10.37	4.82	2.02	3.56	3.17
Price to Tangible Book Value (P/TBV)	4.85	3.55	2.59	3.99	2.34	11.68	10.37	4.82	2.02	5.86	5.27
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,749.89	13.75
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	822.22	591.59	4,034.16	0.00	0.00	228.26	121.10	23.76	5.89	4.99
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,515.35	11.78
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.03	-1.00	-1.00	-1.00	-1.00	-1.01	-0.98	-0.96	-0.96	-0.70	-0.46
Leverage Ratio	1.06	1.02	1.02	1.05	1.04	1.08	1.17	1.21	1.29	1.33	1.31
Compound Leverage Factor	1.06	1.01	1.01	1.04	1.00	1.03	1.15	1.21	1.28	1.29	1.24
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.16%	0.20%	0.17%	0.14%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.16%	0.20%	0.17%	0.14%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	99.84%	99.80%	99.83%	99.86%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.56	1.27	0.65	0.89
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.10	1.71	0.87	1.17
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	76.49	134.84	50.95	32.11	43.90	42.54	34.75	8.62	-0.91	1.13	2.29
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	27.06	63.79	34.12	15.56	33.02	8.10	11.59	5.69	5.24	2.79	3.74
Quick Ratio	27.02	63.62	33.51	15.15	32.54	7.86	11.47	5.65	5.16	2.54	3.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-10	-20	-38	-65	-87	-139	-219	-233	-281	-606	-359
Operating Cash Flow to CapEx	-542.27%	-1,608.14%	-2,147.80%	-7,656.52%	-8,451.50%	-2,297.08%	-438.40%	-606.65%	-1,433.33%	-1,623.24%	-3,188.88%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.19
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.72
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.01
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	1.47
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.36	4.09
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	77.30
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	91.09
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,013.48	89.24
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1,013.48	79.15
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.06	0.32	0.45	0.11	-2.33	-8.11	27	21	22	306	388
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.47
Increase / (Decrease) in Invested Capital	2.00	0.39	0.13	-0.34	-2.44	-5.78	35	-6.48	1.79	283	82
Enterprise Value (EV)	173	266	265	436	622	3,186	6,177	2,492	531	1,802	1,933
Market Capitalization	218	369	432	581	1,090	3,493	6,806	2,995	1,009	2,081	2,255
Book Value per Share	$1.62	$2.17	$2.69	$2.00	$3.78	$2.37	$4.48	$3.96	$3.17	$2.28	$2.33
Tangible Book Value per Share	$1.62	$2.17	$2.69	$2.00	$3.78	$2.37	$4.48	$3.96	$3.17	$1.39	$1.40
Total Capital	45	104	167	145	466	299	656	623	501	586	711
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00
Net Debt	-45	-104	-166	-145	-469	-307	-629	-503	-477	-279	-323
Capital Expenditures (CapEx)	1.59	1.14	1.52	1.03	1.20	6.92	47	38	20	22	11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.60	-1.35	-1.93	-5.68	-7.55	-30	-48	-86	-91	-82	11
Debt-free Net Working Capital (DFNWC)	43	102	165	140	461	277	581	419	388	198	335
Net Working Capital (NWC)	43	102	165	140	461	277	581	419	388	198	335
Net Nonoperating Expense (NNE)	3.61	8.16	15	27	34	53	76	102	117	122	95
Net Nonoperating Obligations (NNO)	-45	-104	-166	-145	-469	-307	-629	-601	-477	-279	-323
Total Depreciation and Amortization (D&A)	0.09	1.00	0.90	0.97	-0.38	4.70	11	20	22	30	33
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6,923.89%	6.64%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16,614.13%	203.98%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16,614.13%	203.98%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.48)	($0.62)	($1.85)	($1.41)	($1.27)	($1.59)	($1.88)	($2.23)	($2.49)	($1.89)	($1.28)
Adjusted Weighted Average Basic Shares Outstanding	44.08M	48.57M	62.31M	89.45M	123.42M	126.50M	146.98M	153.41M	159.26M	235.13M	289.88M
Adjusted Diluted Earnings per Share	($0.48)	($0.62)	($1.85)	($1.41)	($1.27)	($1.59)	($1.88)	($2.23)	($2.49)	($1.89)	($1.28)
Adjusted Weighted Average Diluted Shares Outstanding	44.08M	48.57M	62.31M	89.45M	123.42M	126.50M	146.98M	153.41M	159.26M	235.13M	289.88M
Adjusted Basic & Diluted Earnings per Share	($0.48)	($0.62)	($1.85)	($1.41)	($1.27)	($1.59)	($1.88)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	24.99M	44.41M	55.27M	65.24M	97.28M	124.34M	138.30M	157.17M	224.24M	279.31M	327.88M
Normalized Net Operating Profit after Tax (NOPAT)	-8.43	-20	-38	-65	-90	-145	-183	-240	-279	-322	-277
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-27,114.49%	-168.64%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-37,638.02%	-228.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Iovance Biotherapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	12,969.75%	12,385.07%	15,189.21%
EBITDA Growth	-17.41%	-8.30%	-23.14%	-8.60%	-15.20%	-11.07%	-3.78%	8.39%	26.42%	31.44%
EBIT Growth	-16.41%	-7.61%	-20.87%	-10.38%	-17.90%	-13.29%	-6.19%	7.42%	24.75%	28.60%
NOPAT Growth	-16.41%	-7.61%	-20.87%	-10.38%	-17.90%	-13.29%	-6.19%	7.42%	24.75%	28.60%
Net Income Growth	-15.67%	-6.03%	-17.21%	-7.23%	-14.20%	-10.50%	-5.22%	8.85%	26.56%	32.50%
EPS Growth	-14.55%	-1.56%	13.79%	25.40%	26.98%	29.23%	16.00%	27.66%	39.13%	47.83%
Operating Cash Flow Growth	-10.32%	-44.24%	-35.25%	-21.02%	-32.10%	-8.11%	-22.51%	-4.77%	29.86%	12.71%
Free Cash Flow Firm Growth	49.89%	-21.49%	-10.52%	-280.23%	-584.98%	-380.06%	-424.93%	42.77%	65.88%	61.31%
Invested Capital Growth	-36.97%	8.68%	-18.43%	432.67%	1,014.83%	1,267.20%	805.60%	36.10%	20.19%	26.78%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	97.06%	2.77%	48.34%	4,250.49%	88.24%	25.85%
EBITDA Q/Q Growth	-1.09%	-7.28%	-4.07%	3.78%	-7.23%	-3.43%	2.75%	15.07%	13.87%	3.61%
EBIT Q/Q Growth	-0.66%	-6.61%	-3.57%	0.69%	-7.52%	-2.45%	2.91%	13.43%	12.61%	2.80%
NOPAT Q/Q Growth	-0.66%	-6.61%	-3.57%	0.69%	-7.52%	-2.45%	2.91%	13.43%	12.61%	2.80%
Net Income Q/Q Growth	-0.27%	-5.72%	-1.95%	0.78%	-6.79%	-2.30%	2.92%	14.05%	13.96%	5.96%
EPS Q/Q Growth	0.00%	-3.17%	23.08%	6.00%	2.13%	0.00%	8.70%	19.05%	17.65%	14.29%
Operating Cash Flow Q/Q Growth	18.02%	-22.03%	-28.51%	5.87%	10.50%	0.13%	-45.62%	19.50%	40.09%	-24.29%
Free Cash Flow Firm Q/Q Growth	29.51%	-42.65%	9.20%	-316.44%	-26.99%	0.02%	0.71%	54.60%	24.30%	-13.37%
Invested Capital Q/Q Growth	-42.86%	-20.51%	57.22%	645.88%	19.60%	-2.52%	4.14%	12.10%	5.62%	2.83%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	-761.34%	-825.37%	-805.60%	-915.52%	-0.84%	31.99%	38.20%
EBITDA Margin	0.00%	0.00%	0.00%	-42,908.40%	-23,349.47%	-23,499.79%	-15,405.59%	-300.74%	-137.60%	-105.38%
Operating Margin	0.00%	0.00%	0.00%	-46,254.62%	-25,236.89%	-25,156.85%	-16,464.62%	-327.63%	-152.11%	-117.48%
EBIT Margin	0.00%	0.00%	0.00%	-46,254.62%	-25,236.89%	-25,156.85%	-16,464.62%	-327.63%	-152.11%	-117.48%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	-44,759.66%	-24,255.86%	-24,145.02%	-15,800.84%	-312.16%	-142.67%	-106.60%
Tax Burden Percent	100.00%	100.00%	100.00%	99.55%	98.92%	98.51%	98.77%	98.52%	98.21%	102.02%
Interest Burden Percent	99.23%	98.40%	96.86%	97.20%	97.16%	97.43%	97.16%	96.71%	95.50%	88.94%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-49.48%	-73.09%	-127.63%	-124.13%	-24.28%	-28.02%	-38.92%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-41.51%	-64.57%	-119.30%	-117.98%	-17.20%	-22.42%	-32.95%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	29.21%	43.91%	83.20%	87.01%	9.29%	11.72%	15.31%
Return on Equity (ROE)	-71.41%	-70.61%	-67.55%	-20.27%	-29.18%	-44.43%	-37.12%	-14.98%	-16.30%	-23.61%
Cash Return on Invested Capital (CROIC)	-707.50%	-1,308.81%	-727.49%	-329.32%	-349.91%	-369.25%	-345.31%	-134.42%	-105.50%	-103.43%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-16.09%	-25.52%	-41.42%	-37.00%	-12.47%	-14.99%	-22.80%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-15.57%	-24.53%	-39.75%	-35.51%	-11.88%	-14.06%	-20.69%
Return on Common Equity (ROCE)	-71.41%	-70.61%	-67.55%	-20.27%	-29.18%	-44.43%	-37.12%	-14.98%	-16.30%	-23.61%
Return on Equity Simple (ROE_SIMPLE)	-99.03%	0.00%	-61.73%	-72.39%	-64.24%	0.00%	-66.12%	-57.28%	-53.01%	0.00%
Net Operating Profit after Tax (NOPAT)	-70	-75	-78	-77	-83	-85	-82	-71	-62	-61
NOPAT Margin	0.00%	0.00%	0.00%	-32,378.24%	-17,665.82%	-17,609.79%	-11,525.23%	-229.34%	-106.47%	-82.24%
Net Nonoperating Expense Percent (NNEP)	-5.76%	-5.64%	-5.22%	-7.97%	-8.51%	-8.33%	-6.16%	-7.08%	-5.60%	-5.97%
Return On Investment Capital (ROIC_SIMPLE)	-	-14.97%	-	-	-	-14.49%	-	-	-	-8.52%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	861.34%	925.37%	905.60%	1,015.52%	100.84%	68.01%	61.80%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	9,213.03%	5,749.25%	6,203.94%	4,390.63%	127.20%	67.55%	57.68%
R&D to Revenue	0.00%	0.00%	0.00%	36,280.25%	18,662.26%	18,147.30%	11,158.46%	199.59%	116.55%	98.01%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	45,493.28%	24,411.51%	24,351.24%	15,549.09%	326.79%	184.10%	155.68%
Earnings before Interest and Taxes (EBIT)	-100	-107	-111	-110	-118	-121	-118	-102	-89	-87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-95	-102	-106	-102	-110	-113	-110	-94	-81	-78
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.84	2.02	2.05	2.73	1.67	3.56	5.58	2.92	3.68	3.17
Price to Tangible Book Value (P/TBV)	3.84	2.02	2.05	4.61	2.50	5.86	9.83	4.74	6.11	5.27
Price to Revenue (P/Rev)	0.00	0.00	0.00	6,639.15	1,594.60	1,749.89	1,991.97	68.48	31.37	13.75
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	40.97	23.76	21.00	4.82	2.45	5.89	10.78	5.13	6.51	4.99
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	5,310.07	1,084.88	1,515.35	1,802.04	55.92	27.00	11.78
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.93	-0.96	-0.94	-0.70	-0.68	-0.70	-0.74	-0.54	-0.52	-0.46
Leverage Ratio	1.26	1.29	1.25	1.30	1.31	1.33	1.26	1.28	1.27	1.31
Compound Leverage Factor	1.25	1.26	1.21	1.27	1.27	1.30	1.22	1.24	1.22	1.16
Debt to Total Capital	0.25%	0.20%	0.15%	0.17%	0.15%	0.17%	0.15%	0.13%	0.13%	0.14%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.25%	0.20%	0.15%	0.17%	0.15%	0.17%	0.15%	0.13%	0.13%	0.14%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.75%	99.80%	99.85%	99.83%	99.85%	99.83%	99.85%	99.87%	99.87%	99.86%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.97	1.27	1.59	0.78	0.86	0.65	0.83	0.97	1.00	0.89
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	1.31	1.71	2.16	1.05	1.15	0.87	1.11	1.28	1.32	1.17
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.24	0.54	2.72	1.83	0.63	2.56	8.54	3.82	4.85	3.41
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.67	5.24	7.31	3.10	4.21	2.79	4.63	5.15	4.22	3.74
Quick Ratio	4.55	5.16	7.18	2.83	3.97	2.54	4.28	4.74	3.84	3.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-54	-77	-70	-290	-368	-368	-366	-166	-126	-142
Operating Cash Flow to CapEx	-4,588.97%	-2,570.19%	-1,762.27%	-986.89%	-2,350.66%	-2,379.43%	-2,931.65%	-22,269.00%	-2,577.49%	-1,758.54%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.10	0.19
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.07	0.00	4.72
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.52	3.47	4.01
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.01	0.01	0.02	0.29	0.81	1.47
Accounts Payable Turnover	0.00	0.00	0.00	0.08	0.29	0.36	0.63	1.84	3.25	4.09
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	176.18	0.00	77.30
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	144.87	105.28	91.09
Days Payable Outstanding (DPO)	0.00	0.00	0.00	4,555.02	1,243.20	1,013.48	580.16	198.84	112.30	89.24
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	-4,555.02	-1,243.20	-1,013.48	-580.16	122.21	-7.02	79.15
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	28	22	35	262	314	306	318	357	377	388
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.11	0.26	0.47
Increase / (Decrease) in Invested Capital	-17	1.79	-7.94	213	286	283	283	95	63	82
Enterprise Value (EV)	1,153	531	738	1,264	767	1,802	3,431	1,833	2,454	1,933
Market Capitalization	1,512	1,009	1,370	1,580	1,127	2,081	3,793	2,244	2,850	2,255
Book Value per Share	$2.50	$3.17	$2.97	$2.58	$2.72	$2.28	$2.55	$2.75	$2.55	$2.33
Tangible Book Value per Share	$2.50	$3.17	$2.97	$1.53	$1.82	$1.39	$1.45	$1.69	$1.54	$1.40
Total Capital	395	501	668	580	675	586	681	770	774	711
Total Debt	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Total Long-Term Debt	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net Debt	-359	-477	-632	-316	-360	-279	-362	-412	-396	-323
Capital Expenditures (CapEx)	1.39	3.02	5.66	9.52	3.58	3.53	4.17	0.44	2.29	4.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-70	-91	-82	-131	-70	-82	-60	-24	-17	11
Debt-free Net Working Capital (DFNWC)	291	388	551	186	292	198	302	389	381	335
Net Working Capital (NWC)	291	388	551	186	292	198	302	389	381	335
Net Nonoperating Expense (NNE)	29	30	30	29	31	31	31	26	21	18
Net Nonoperating Obligations (NNO)	-366	-477	-632	-316	-360	-279	-362	-412	-396	-323
Total Depreciation and Amortization (D&A)	5.34	5.05	4.72	7.96	8.85	7.99	7.57	8.37	8.49	8.92
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	-55,079.41%	-9,864.64%	-6,923.89%	-3,167.33%	-73.23%	-18.67%	6.64%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	78,250.00%	41,249.08%	16,614.13%	15,878.10%	1,185.82%	418.81%	203.98%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	78,250.00%	41,249.08%	16,614.13%	15,878.10%	1,185.82%	418.81%	203.98%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.63)	($0.65)	($0.50)	($0.47)	($0.46)	($0.46)	($0.42)	($0.34)	($0.28)	($0.24)
Adjusted Weighted Average Basic Shares Outstanding	157.82M	159.26M	213.69M	224.48M	245.82M	235.13M	266.22M	284.82M	303.27M	289.88M
Adjusted Diluted Earnings per Share	($0.63)	($0.65)	($0.50)	($0.47)	($0.46)	($0.46)	($0.42)	($0.34)	($0.28)	($0.24)
Adjusted Weighted Average Diluted Shares Outstanding	157.82M	159.26M	213.69M	224.48M	245.82M	235.13M	266.22M	284.82M	303.27M	289.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	157.84M	224.24M	224.45M	247.78M	255.92M	279.31M	279.83M	303.51M	304.78M	327.88M
Normalized Net Operating Profit after Tax (NOPAT)	-70	-75	-78	-77	-83	-85	-82	-71	-62	-61
Normalized NOPAT Margin	0.00%	0.00%	0.00%	-32,378.24%	-17,665.82%	-17,609.79%	-11,525.23%	-229.34%	-106.47%	-82.24%
Pre Tax Income Margin	0.00%	0.00%	0.00%	-44,960.08%	-24,520.90%	-24,509.96%	-15,997.76%	-316.85%	-145.27%	-104.49%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Iovance Biotherapeutics' Financials

When does Iovance Biotherapeutics's fiscal year end?

According to the most recent income statement we have on file, Iovance Biotherapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Iovance Biotherapeutics' net income changed over the last 10 years?

Iovance Biotherapeutics' net income appears to be on an upward trend, with a most recent value of -$372.18 million in 2024, rising from -$12.04 million in 2014. The previous period was -$444.04 million in 2023.

What is Iovance Biotherapeutics's operating income?

Iovance Biotherapeutics's total operating income in 2024 was -$395.28 million, based on the following breakdown:

Total Gross Profit: $40.08 million
Total Operating Expenses: $435.35 million

How has Iovance Biotherapeutics revenue changed over the last 10 years?

Over the last 10 years, Iovance Biotherapeutics' total revenue changed from $0.00 in 2014 to $164.07 million in 2024, a change of 16,407,000,000.0%.

How much debt does Iovance Biotherapeutics have?

Iovance Biotherapeutics' total liabilities were at $200.02 million at the end of 2024, a 2.2% increase from 2023, and a 11,935.0% increase since 2014.

How much cash does Iovance Biotherapeutics have?

In the past 10 years, Iovance Biotherapeutics' cash and equivalents has ranged from $13.97 million in 2019 to $231.73 million in 2022, and is currently $115.69 million as of their latest financial filing in 2024.

How has Iovance Biotherapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Iovance Biotherapeutics' book value per share changed from 1.62 in 2014 to 2.33 in 2024, a change of 43.7%.

Related Companies

This page (NASDAQ:IOVA) was last updated on 4/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Financials

Frequently Asked Questions About Iovance Biotherapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Financials

Annual Income Statements for Iovance Biotherapeutics

Quarterly Income Statements for Iovance Biotherapeutics

Annual Cash Flow Statements for Iovance Biotherapeutics

Quarterly Cash Flow Statements for Iovance Biotherapeutics

Annual Balance Sheets for Iovance Biotherapeutics

Quarterly Balance Sheets for Iovance Biotherapeutics

Annual Metrics and Ratios for Iovance Biotherapeutics

Quarterly Metrics and Ratios for Iovance Biotherapeutics

Frequently Asked Questions About Iovance Biotherapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools